Mutant respiratory syncytial virus pre-fusion F protein and application thereof

• Main Authors: ZHANG JIANCHENG, RUAN BAOYANG, SHI ZHAORONG, CAO YUFENG, YI XIAONAN, LIU LIN, SHI LI, CHEN XIAOYU
• Format: Patent
• Language: Chinese; English
• Published: 23.06.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention relates to the technical field of bioengineering, in particular to a mutant respiratory syncytial virus pre-fusion F protein and application thereof. Compared with a wild type respiratory syncytial virus pre-fusion F protein, the mutant respiratory syncytial virus pre-fusion F protein provided by the invention has the following mutations: (a) at least one amino acid residue in an F1 subunit and/or an F2 subunit is substituted by cysteine; (b) amino acid residues at the 104th-144th site of the F protein before fusion of the wild-type respiratory syncytial virus are partially or completely substituted by a connecting peptide, and the length of the amino acid residues of the connecting peptide is at least 2. Compared with similar products, the mutant respiratory syncytial virus pre-fusion F protein has excellent neutralizing antibody binding activity and thermal stability, and is suitable for being developed into one of components of respiratory syncytial virus vaccines. 本发明涉及生物工程技术领域，尤其是涉及突变型呼吸道合胞